Salama, J K <br/><br/>
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2011 
 - 2304-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq736  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Squamous Cell--drug therapy<br/>Combined Modality Therapy<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Hydroxyurea--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Radiotherapy Dosage<br/>Squamous Cell Carcinoma of Head and Neck